AbCellera Biologics (ABCL) Total Current Liabilities (2020 - 2026)

AbCellera Biologics has reported Total Current Liabilities for 7 years, with the latest figure at $47.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 37.27% year-over-year to $47.3 million; the trailing twelve-month figure through Mar 2026 stood at $47.3 million (down 37.27% YoY), and the FY2025 full-year result was $64.3 million, down 16.06% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $47.3 million, down from $64.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $221.1 million in Q2 2022, with the low at $47.3 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $103.0 million across 5 years, with a median of $89.6 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 217.01% — and 2023, when it sank 58.02%.
• AbCellera Biologics' Total Current Liabilities stood at $118.3 million in 2022, then advanced by 0.59% to $119.0 million in 2023, then plunged by 35.63% to $76.6 million in 2024, then fell by 16.06% to $64.3 million in 2025, then dropped by 26.46% to $47.3 million in 2026.
• The last three Total Current Liabilities figures came in at $47.3 million (Q1 2026), $64.3 million (Q4 2025), and $68.8 million (Q3 2025), per Business Quant data.